Product
StromaForte
Aliases
Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)
4 clinical trials
4 indications
Indication
Cardiovascular DiseasesIndication
frailtyIndication
Aging FrailtyIndication
Osteoarthritis of the KneeClinical trial
A Longitudinal Open-Label Multi-center Single-Arm Phase I/IIa Study to Evaluate the Safety and Preventive Effect on Cardiovascular Events of Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product, StromaForte, in Study Participants.Status: Recruiting, Estimated PCD: 2029-10-06
Clinical trial
A Patient Sponsored Ongoing Open-label Single-arm, Safety and Efficacy, Phase I/IIa Clinical Study of Cellcolabs' Human Allogeneic Bone-marrow-derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Aging FrailtyStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
An Open-Label Single-Arm Phase I/IIa Study to Evaluate the Safety of Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product StromaForte in Patients With Aging FrailtyStatus: Recruiting, Estimated PCD: 2024-11-28
Clinical trial
An Open-Label Single-Arm Phase I/IIa Study to Evaluate the Safety of Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product StromaForte for the Treatment of Knee OsteoarthritisStatus: Recruiting, Estimated PCD: 2024-11-08